StockData
Ironwood Pharmaceuticals Inc logo

Ironwood Pharmaceuticals Inc (IRWD) stock

IRWDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3063% below fair value
$4.87+0.02 (+0.41%)

Close on Nov 17, 2026Market cap $804.72MP/E 6.3Yield –

Ironwood Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Ironwood Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was $234.17M, up 219.3% year over year. For fiscal 2025 it was $98.50M, up 5.8% from the year before. The highest annual figure on record is $250.34M in fiscal 2022.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$98.50M+5.8%
FY2024Dec 31, 2024$93.12M–
FY2023Dec 31, 2023-$945.43M-477.7%
FY2022Dec 31, 2022$250.34M+7.8%
FY2021Dec 31, 2021$232.26M+62.5%
FY2020Dec 31, 2020$142.94M+19.0%
FY2019Dec 31, 2019$120.12M–
FY2018Dec 31, 2018-$150.67M–
FY2017Dec 31, 2017-$15.36M–
FY2016Dec 31, 2016-$51.87M–
FY2015Dec 31, 2015-$102.09M–
FY2014Dec 31, 2014-$169.37M–
FY2013Dec 31, 2013-$252.00M–
FY2012Dec 31, 2012-$72.76M–
FY2011Dec 31, 2011-$66.14M–
FY2010Dec 31, 2010-$60.77M–
FY2009Dec 31, 2009-$60.82M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$79.31M+75.0%
Q1 FY2026Mar 31, 2026$72.57M–
Q4 FY2025Dec 31, 2025$6.81M-78.4%
Q3 FY2025Sep 30, 2025$75.48M+194.4%
Q2 FY2025Jun 30, 2025$45.32M+81.5%
Q1 FY2025Mar 31, 2025-$29.11M-364.1%
Q4 FY2024Dec 31, 2024$31.49M-16.2%
Q3 FY2024Sep 30, 2024$25.64M-35.9%
Q2 FY2024Jun 30, 2024$24.98M–
Q1 FY2024Mar 31, 2024$11.02M-81.7%
Q4 FY2023Dec 31, 2023$37.59M-45.0%
Q3 FY2023Sep 30, 2023$40.02M-41.5%
Q2 FY2023Jun 30, 2023-$1.08B-2046.2%
Q1 FY2023Mar 31, 2023$60.10M+3.9%
Q4 FY2022Dec 31, 2022$68.36M+20.8%
Q3 FY2022Sep 30, 2022$68.47M+5.1%
Q2 FY2022Jun 30, 2022$55.66M-14.5%
Q1 FY2022Mar 31, 2022$57.85M+27.4%
Q4 FY2021Dec 31, 2021$56.59M+10.1%
Q3 FY2021Sep 30, 2021$65.17M+42.9%
Q2 FY2021Jun 30, 2021$65.10M+99.0%
Q1 FY2021Mar 31, 2021$45.40M+243.2%
Q4 FY2020Dec 31, 2020$51.38M+3.6%
Q3 FY2020Sep 30, 2020$45.62M-30.8%
Q2 FY2020Jun 30, 2020$32.71M+51.6%
Q1 FY2020Mar 31, 2020$13.23M–
Q4 FY2019Dec 31, 2019$49.59M+66.1%
Q3 FY2019Sep 30, 2019$65.89M–
Q2 FY2019Jun 30, 2019$21.58M–
Q1 FY2019Mar 31, 2019-$16.93M–
Q4 FY2018Dec 31, 2018$29.86M-64.8%
Q3 FY2018Sep 30, 2018-$146.57M–
Q2 FY2018Jun 30, 2018-$14.68M–
Q1 FY2018Mar 31, 2018-$35.87M–
Q4 FY2017Dec 31, 2017$84.79M–
Q3 FY2017Sep 30, 2017-$19.43M–
Q2 FY2017Jun 30, 2017-$41.01M–
Q1 FY2017Mar 31, 2017-$39.71M–
Q4 FY2016Dec 31, 2016-$6.30M–
Q3 FY2016Sep 30, 2016-$28.29M–

More Ironwood Pharmaceuticals figures

See a number that looks wrong?